JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Lowers Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) but lowers the price target from $34 to $33.
August 06, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Syndax Pharmaceuticals but lowers the price target from $34 to $33.
The Overweight rating suggests a positive outlook, but the slight reduction in the price target may indicate some caution. The overall impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100